Crinetics Pharmaceuticals Announced That Data From Six Abstracts, Including Oral Presentations Featuring Palsonify (Paltusotine) And Investigational Candidate Atumelnant, Will Be Presented At The Endocrine Society's Annual Meeting In Chicago